医学
壳核
多巴胺转运体
帕金森病
内科学
心脏病学
病理
磁共振弥散成像
疾病
作者
Haijia Mao,Yao Zhang,Mingyue Zou,Sangying Lv,Jiajun Zou,Ya'nan Huang,Minming Zhang,Zhenhua Zhao,Peiyu Huang
标识
DOI:10.1016/j.ejrad.2022.110441
摘要
Abstract
Background
Cerebral small vessel disease (SVD) related brain changes have been found associated with various clinical symptoms of Parkinson disease (PD). On the other hand, PD pathology and treatment may also accelerate SVD progression. Objective
The aim of this study is to explore the interplay between SVD and PD pathology using longitudinal dataset. Methods
We screened 66 healthy controls (HCs) and 114 patients from the Parkinson Progression Markers Initiative (PPMI) database. The peak width of skeletonized mean diffusivity (PSMD) was quantified from diffusion tensor images to reflect vascular pathologies at baseline and 24 months follow-up, and dopamine transporter (DAT) imaging data was used to represent the extent of dopaminergic neuronal degeneration at the same point time. We compared the PSMD between PD patients and HCs, and analyzed whether PSMD and DAT availability could predict each other's progression using multiple regression analyses in PD patients. Results
PSMD at baseline had no significant difference between the HCs and patients with PD (P = 0.169). Higher baseline PSMD was associated with less DAT reduction in the caudate (β = 0.216, P = 0.029), but not the putamen (β = 0.058, P = 0.552) in PD patients. Baseline caudate and putamen DAT availability had no significant association with PSMD progression (β = -0.006, P = 0.950; β = 0.017, P = 0.860, respectively). Conclusions
Mild SVD might slow down PD pathology progression, while the effect of PD pathology on the progression of SVD was not significant.
科研通智能强力驱动
Strongly Powered by AbleSci AI